14-day Premium Trial Subscription Try For FreeTry Free
NASDAQ:EARS
Delisted

Auris Medical Holding AG Stock Price (Quote)

$0.750
-0.0010 (-0.133%)
At Close: May 27, 2022

Range Low Price High Price Comment
30 days $141.16 $183.01 Friday, 27th May 2022 EARS stock ended at $0.750. This is 0.133% less than the trading day before Thursday, 26th May 2022. During the day the stock fluctuated 10.68% from a day low at $0.740 to a day high of $0.82.
90 days $141.16 $227.30
52 weeks $84.73 $227.30

Historical Auris Medical Holding AG prices

Date Open High Low Close Volume
Jan 14, 2019 $0.456 $0.456 $0.415 $0.431 482 680
Jan 11, 2019 $0.444 $0.460 $0.425 $0.425 439 437
Jan 10, 2019 $0.451 $0.458 $0.430 $0.445 331 903
Jan 09, 2019 $0.456 $0.462 $0.400 $0.460 874 195
Jan 08, 2019 $0.470 $0.485 $0.450 $0.461 877 288
Jan 07, 2019 $0.500 $0.501 $0.460 $0.464 953 554
Jan 04, 2019 $0.480 $0.530 $0.477 $0.490 878 578
Jan 03, 2019 $0.460 $0.494 $0.460 $0.475 825 036
Jan 02, 2019 $0.450 $0.480 $0.450 $0.454 933 285
Dec 31, 2018 $0.485 $0.542 $0.450 $0.456 2 395 959
Dec 28, 2018 $0.417 $0.528 $0.416 $0.486 2 607 229
Dec 27, 2018 $0.405 $0.410 $0.370 $0.400 575 667
Dec 26, 2018 $0.350 $0.400 $0.350 $0.391 1 077 640
Dec 24, 2018 $0.368 $0.440 $0.320 $0.385 2 845 868
Dec 21, 2018 $0.361 $0.361 $0.305 $0.311 978 367
Dec 20, 2018 $0.390 $0.400 $0.320 $0.357 1 187 044
Dec 19, 2018 $0.375 $0.410 $0.370 $0.385 832 260
Dec 18, 2018 $0.410 $0.411 $0.379 $0.390 1 092 710
Dec 17, 2018 $0.431 $0.450 $0.413 $0.413 728 154
Dec 14, 2018 $0.462 $0.469 $0.415 $0.435 982 521
Dec 13, 2018 $0.460 $0.479 $0.440 $0.452 1 408 947
Dec 12, 2018 $0.460 $0.470 $0.411 $0.469 2 619 838
Dec 11, 2018 $0.498 $0.510 $0.456 $0.465 2 894 241
Dec 10, 2018 $0.549 $0.549 $0.508 $0.533 1 286 598
Dec 07, 2018 $0.561 $0.590 $0.550 $0.554 1 469 762
Click to get the best stock tips daily for free!

About Auris Medical Holding AG

Auris Medical Holding AG Auris Medical Holding AG, a clinical-stage biopharmaceutical company, focuses on the development of novel products for the treatment of inner ear disorders. Its lead product candidate includes AM-101, which is in Phase III clinical development for treating acute inner ear tinnitus. The company is also developing AM-111 for the treatment of acute sensorineural hearing loss; and other pre-clinical stage products comprising AM-102 and AM-123. It has... EARS Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT